Gammagard Problematic for Success in Mild-to-Moderate Alzheimer’s: Now, AttorneyOne Can Provide Advice for Legal Counsel in Cases of Side Effects

On January 22nd 2013, the Financial Times published that Phase III Gammagard clinical trial has been met with reservation from experts, who cited the mild-to-moderate patient population as problematic for success in treating Alzheimer’s disease. In light of these news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel, to people potentially affected by Gammagard side effects. http://www.attorneyone.com/gammagard-lawsuits/

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Gammagard: severe adverse events

Gammagard: severe adverse events

1,296 reports of a serious adverse event where Gammagard Liquid was identified as the primary suspect drug causing that event

San Diego, CA (PRWEB) January 24, 2013

AttorneyOne.com, a recognized authority on law, updated the website recently and is now actively providing expert opinion in view of the recent news on Gammaguard.

On January 22nd 2013, the Financial Times published that Phase III Gammagard clinical trial has been met with reservation from experts, who cited the mild-to-moderate patient population as problematic for success in treating Alzheimer’s disease. Gammagard is an intravenous solution that is made from human plasma. It is a sterile solution, which helps the body maintain immunity and fight disease.

Baxter discontinued manufacture of Gammagard S/D as of December 2012, as reported by the Immune Deficiency Foundation on August 6th, 2012. Adverse Events published that, from November 1st 1997 to June 30th 2012, there have been 1,296 reports of a serious adverse event where Gammagard Liquid was identified as the primary suspect drug causing that event (FDA AERS Reports).

Taking into consideration the latest developments, AttorneyOne.com updated the website and, now, can actively provide an expert opinion including how to get in contact with legal counsel easily and inexpensively in case of alleged Gammagard severe complications. As Mr. Burke, director of Media Relations for AttorneyOne.com, added, “What all this information really illustrates is that the alleged threat from Gammagard remains. For that reason", he continues, "our focus should squarely fall on getting the word out and assisting people in finding the right legal assistance.”

On June 4th, 2010, the US FDA notified healthcare professionals of a market withdrawal being conducted as a precautionary measure due to an increased number of adverse event reports of allergic reactions associated with two lots of Gammagard.

AttorneyOne.com has further information on Gammagard lawsuits including how to get in contact with legal counsel.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2013/1/prweb10349586.htm.